Trials / Withdrawn
WithdrawnNCT02192489
A Phase 2 Study With CC-220 in Skin Sarcoidosis
A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
Detailed description
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, sequential, dose-ascending, safety and tolerability study in subjects with chronic cutaneous sarcoidosis. Two dose cohorts of CC-220 (Cohort 1: 0.3 mg by mouth (PO) every day (QD) or matching placebo and Cohort 2: 0.6 mg PO QD or matching placebo) will be evaluated using a sequential, dose-ascending design
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-220 0.3 mg Daily | |
| DRUG | CC-220 0.6mg Daily | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-06-30
- Completion
- 2017-06-30
- First posted
- 2014-07-16
- Last updated
- 2019-11-12
Source: ClinicalTrials.gov record NCT02192489. Inclusion in this directory is not an endorsement.